Joachim Eeckhout, Author at Labiotech.eu

About

Founder & Managing Director at Labiotech.eu. While I was studying biotechnology in Paris, I got frustrated by the lack of digital media available for the industry and decided to fix it! I launched Labiotech.eu in 2014 and grew it to the largest community for biotech professionals in Europe! Other than biotech news, I’m also a heavy reader of Sci-Fi and Fantasy.

Articles by Joachim Eeckhout

News and Trends 8 Jan 2015

Nanobiotix on its way to change the paradigm in cancer therapy

Nanobiotix is an oncology focused nanomedicine company developing an innovative nanoparticle technology. Their NanoXray technology comprises three products having the potential to cause a paradigm shift in cancer therapy. NanoXray products are developed to selectively increase the efficacy of radiotherapy in the tumor cell. The following video is showing how this disruptive technology is acting […]

January 8, 2015 - 4 minutesmins - By Joachim Eeckhout

News and Trends 22 Dec 2014

Biotech’s crowdfunding: is France top of the class?

No need to present the crowdfunding again! We hear about it every day through Kickstarter’s projects or other platforms that abound on the web. But what about biotech’s crowdfunding? Through many French entrepreneur’s interviews who are engaged in crowdfunding’s campaigns, I tried to make my own idea about this new financing tool. And one thing […]

December 22, 2014 - 5 minutesmins - By Joachim Eeckhout

News and Trends 14 Nov 2014

Onxeo confirms receipt of the $25M milestone payment from its US partner Spectrum

Onxeo, an innovative company specializing in the development of orphan oncology drugs, founded after the merger of BioAlliance Pharma and Topotarget, announces that it has received from his US partner Spectrum Pharmaceuticals the milestone payment of $25 million related to the approval of Beleodaq by the FDA. Early July 2014, Beleodaq was granted by the […]

November 14, 2014 - 3 minutesmins - By Joachim Eeckhout

News and Trends 13 Nov 2014

BIO-Europe, “The place to be for partnering in Europe”

The title may seem a bit catchy, but that’s what lot of companies told me during my visit at BIO-Europe 2014 in Francfort. Why is it so? Surely because of the high profile of attendees, attracted by the prestigious brand and the leadership of BIO’s events. To open the cession, Anna Chrisman, Group managing Director of […]

November 13, 2014 - 3 minutesmins - By Joachim Eeckhout

News and Trends 8 Oct 2014

Baden-Württemberg Healthcare Industry Forum 2014, discover one of the largest cluster in Germany

Last September 24th was held the Baden-Württemberg Healthcare Industry Forum 2014, organized by BIOPRO the biotech cluster of this German region. It was an opportunity to review the bilan of the cluster and to learn interesting facts. BIOPRO has listed 159 biotech companies in the Baden-Württemberg area, representing a workforce of more than 22,000 employees and a turnover […]

October 8, 2014 - 6 minutesmins - By Joachim Eeckhout

Carmat polemic intelligent artificial heart

News and Trends 24 Sep 2014

The Polemic of First Intelligent Artificial Heart

The first intelligent artificial heart has been twice implanted in France within clinical trials. It has been developed by French company Carmat, and famous cardiologist Alain Carpentier, after 20 years of development. This important breakthrough nevertheless create a polemic. Artificial hearts already existed and voice talks about an artificial financial bubble around Carmat. On September 11th, […]

September 24, 2014 - 4 minutesmins - By Joachim Eeckhout

News and Trends 4 Sep 2014

Art Levinson says goodbye to Roche and will focus on Calico’s development

Roche announced today that Arthur D. Levinson has resigned from the Board of Directors, effective immediately. Arthur D. Levinson made this decision so as to avoid any conflict of interest given his role as Chief Executive Officer at Calico. “I would like to thank Art for his many important contributions, both as a member […]

September 4, 2014 - 3 minutesmins - By Joachim Eeckhout

News and Trends 3 Sep 2014

Affimed secures almost $30M in Financing to continue its clinical development

Affimed Therapeutics today announced that it has closed a $15.7 million (€11.7 million) Series E equity funding led by Affimed’s current investors Aeris Capital, BioMedInvest, LSP Life Sciences Partners, Novo Nordisk A/S and Orbimed. In addition, the Company has signed a $14 million (€10.5 million) loan agreement with Perceptive Advisors, leading to a total of […]

September 3, 2014 - 2 minutesmins - By Joachim Eeckhout

News and Trends 3 Sep 2014

EMA give Orphan Drug Designation to the CER-001 of Cerenis

Cerenis Therapeutics, the biopharmaceutical company developing CER-001, an engineered human apoA-I-containing pre-beta HDL mimetic, for the treatment of cardiovascular disease, announced today that it has received two separate Orphan Drug Designations from the European Medicines Agency (EMA) for the use of CER-001 in the treatment of patients with rare genetic defects in HDL synthesis/maturation pathways, […]

September 3, 2014 - 3 minutesmins - By Joachim Eeckhout

News and Trends 27 Aug 2014

Synpromics successfully use synthetic biology in plant science projects

Synpromics, a Scottish-based synthetic biology company today announced that it has successfully generated several highly effective synthetic promoters for use in plants. Dr Michael Roberts, Founder and CSO, said: “We have now shown that our highly disruptive technology platform can be extended from human life science into plant science. Whilst this was always expected, we […]

August 27, 2014 - 2 minutesmins - By Joachim Eeckhout

News and Trends 26 Aug 2014

Adocia launches a Phase III in India for its Diabetic Foot Ulcer treatment

Adocia announced today the initiation of a clinical Phase III study in India of BioChaperone PDGF-BB, the company’s innovative formulation of Platelet Derived Growth Factor (PDGF-BB) for the treatment of diabetic foot ulcers. This follows the approval given by the Drug Controller General of India (DCGI) on August 22nd, 2014. The dossier for this clinical […]

August 26, 2014 - 3 minutesmins - By Joachim Eeckhout

News and Trends 25 Aug 2014

KalVista start the clinical development of a new treatment for diabetic macular edema

KalVista Pharmaceuticals, an ophthalmology company with a focus on diabetic macular edema (DME), today announces that it has begun a Phase I, First in Human, trial of its novel plasma kallikrein inhibitor, KVD001, for the treatment of DME. The study’s principal investigator is Dr. Jennifer K Sun of the Beetham Eye Institute, Joslin Diabetes Center. […]

August 25, 2014 - 3 minutesmins - By Joachim Eeckhout

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Joachim Eeckhout

About

Articles by Joachim Eeckhout

Nanobiotix on its way to change the paradigm in cancer therapy

Biotech’s crowdfunding: is France top of the class?

Onxeo confirms receipt of the $25M milestone payment from its US partner Spectrum

BIO-Europe, “The place to be for partnering in Europe”

Baden-Württemberg Healthcare Industry Forum 2014, discover one of the largest cluster in Germany

The Polemic of First Intelligent Artificial Heart

Art Levinson says goodbye to Roche and will focus on Calico’s development

Affimed secures almost $30M in Financing to continue its clinical development

EMA give Orphan Drug Designation to the CER-001 of Cerenis

Synpromics successfully use synthetic biology in plant science projects

Adocia launches a Phase III in India for its Diabetic Foot Ulcer treatment

KalVista start the clinical development of a new treatment for diabetic macular edema

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

About

Articles by Joachim Eeckhout

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!